Allergan
Reaction mixed to Biohaven’s migraine drug results
March 27, 2018Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical
Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …
Allergan navigating choppy waters, as shares rise and fall
March 16, 2018Medical Communications Allergan, Brent Saunders, biotech, drugs, pharma, pharmaceutical
By most measures Allergan has not had the most successful of years and one measure, in particular, is usually indicative …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
Allergan’s patent gamble fails
February 27, 2018Manufacturing and Production, Medical Communications Allergan, Mylan, biotech, drugs, patent, pharma, pharmaceutical
Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review …
Insider Interview: Allergan’s R&D Chief on plans to be “the headache company”
February 22, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, David Nicholson, Insider Interview, migraine, pharma
Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the …
Top Ten most popular articles on Pharmafile.com this week
February 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma
It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …
Allergan bolsters skincare portfolio with Elastagen acquisition for $95 million
February 7, 2018Research and Development, Sales and Marketing Allergan, Elastagen, M&A, MA, pharma
Pharma’s M&A train keeps on going as news breaks that Allergan has picked up University of Sydney spin-off Elastagen for …
New breakthrough for CGRP migraine treatments
February 6, 2018Research and Development Allergan, Amgen, CGRP, Novartis, biotech, drugs, pharma, pharmaceutical
Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. …
Allergan successfully concludes CFO search
February 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, biotech, drugs, pharma, pharmaceutical
Allergan has been searching for a new Chief Financial Officer since Tessa Hilado, its current CFO, revealed that she would …
Allergan’s Avycaz becomes first FDA-approved gram-negative antibiotic in over 15 years
February 2, 2018Medical Communications, Sales and Marketing Allergan, Avycaz, FDA, pharma, pneumonia
Allergan has announced that the FDA has awarded approval to its fixed-dose combination antibacterial Avycaaz (ceftazidme and avibactam) for the …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
Allergan to axe over 1,000 positions in cost cutting measures
January 4, 2018Sales and Marketing Allergan, biotech, drugs, pharma, pharmaceutical
Allergan was never far away from the headlines in 2017, particularly when it came to its second highest selling product, …
Allergan and Gedeon Richter’s Vraylar posts strong Phase 3 data in bipolar depression
December 19, 2017Manufacturing and Production, Research and Development Allergan, Gedeon Richter, Vraylar, bipolar, bipolar depression, pharma
Vraylar (cariprazine), a drug developed as part of a partnership between Allergan and Gedeon Richter, has demonstrated strong results at …
Allergan ready to take a loss by selling Teva shares
November 2, 2017Sales and Marketing Allergan, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million …
Allergan’s patent shield – The (Native) American dream?
October 17, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, biotech, drugs, pharma, pharmaceutical
In an unprecedented move, leading global pharmaceutical company Allergan appears to have handed its Orange Book-listed US patents covering …
